Hormone replacement therapy and coronary heart disease in women: A review of the evidence

American Journal of the Medical Sciences

Volumn 324, Issue 4, 2002, Pages 180-184

  Low, Annette K ^a   Russell, Lori D ^a   Holman, Honey E ^a   Shepherd, Jinna M ^a   Hicks, G Swink ^a   Brown, C Andrew ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

Coronary heart disease; Hormone replacement therapy; Review

Indexed keywords

CONJUGATED ESTROGEN; ESTROGEN; GESTAGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PROGESTERONE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TRIACYLGLYCEROL;

BREAST CANCER; CLINICAL TRIAL; CONFERENCE PAPER; HEART INFARCTION; HEART PROTECTION; HORMONE SUBSTITUTION; HUMAN; ISCHEMIC HEART DISEASE; MORTALITY; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIMARY PREVENTION; RISK FACTOR; SECONDARY PREVENTION;

EID: 0036789376     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-200210000-00003     Document Type: Conference Paper

References (30)

1. Hoyert DL, Kochanek KD, Murphy S. Deaths: final data for 1997. Natl Vital Stat Rep 1999;47:1-104.
2. Gallop Survey conducted for the American Women's Medical Association, February-March, 1995.
3. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016-37.
4. Chandra NC, Ziegelstein RC, Rogers WJ, et al. Observations of the treatment of women in the United States with myocardial infarction. A report from the National Registry of Myocardial Infarction-I. Arch Intern Med 1998;158:981-8.
5. Marrugat J, Sala J, Masia R, et al. Mortality differences between men and women following first myocardial infarction. JAMA 1998;280:1405-9.
6. Kannel WB. Metabolic risk factors for coronary heart disease in women: perspective from the Framingham Study. Am Heart J 1987;114:413-9.
7. Wuerst JH, Dry TJ, Edwards JE. The degree of coronary atherosclerosis in bilaterally oophorectomized women. Circulation 1953;7:801-9.
8. van der Schouw YT, van der Graff Y, Steyerberg EW, et al. Age at menopause as a risk factor for cardiovascular mortality. Lancet 1996;347:714-8.
9. Genant H, Lucas J, Weiss S, et al. Low-dose esterified estrogen therapy: effects on bone, plasma estradiol concentration, endometrium, and lipid levels. Estratab/Osteoporosis Study Group. Arch Intern Med 1997;157:2609-15.
10. Chae CU, Ridker PM, Manson JE. Postmenopausal hormone replacement therapy and cardiovascular disease. Thromb Haemost 1997;78:770-80.
11. Shlipak MG, Simon JA, Vittinghoff E, et al. Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA 2000;283:1845-52.
12. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999;340: 1801-11.
13. Barrett-Connor E, Grady D. Hormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health 1998;19:55-72.
14. Stampfer MJ, Willett WC, Colditz GA, et al. A prospective study of postmenopausal estrogen therapy and coronary heart disease. N Engl J Med 1985;313:1044-9.
15. Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. N Engl J Med 1991;325:756-62.
16. Grodstein F, Stampfer MJ, Manson JE, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996;335:453-61.
17. Grodstein F, Manson JE, Colditz GA, et al. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000;133:933-41.
18. Sullivan J, Zwaag R, Hughes J, et al. Estrogen replacement and coronary artery disease. Arch Intern Med 1990;150:2557-62.
19. Anonymous. The Coronary Drug Project. Findings leading to discontinuation of the 2.5-mg day estrogen group. The coronary Drug Project Research Group. JAMA 1973;226:652-7.
20. Anonymous. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 1995;273:199-208.
21. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group JAMA 1998;280:605-13.
22. Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000;343: 522-9.
23. Anonymous. Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Control Clin Trials 1998;19:61-109.
24. Lenfant C. Statement from Claude Lenfant, MD, Director, National Heart, Lung, and Blood Institute, on preliminary trends in the Women's Health Initiative. National Heart, Lung, and Blood Institute Communications Office. 2000 April 3.
25. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-88.
26. Mosca L, Barrett-Connor E, Wenger N, et al. Design and methods of the Raloxifene Use for The Heart (RUTH) study. Am J Cardiol 2001;88:392-5.
27. Anonymous. Influence of adherence to treatment and response of cholesterol on mortality in the coronary drug project. N Engl J Med 1980;303:1038-41.
28. Gallagher EJ, Viscoli CM, Horowitz RI. The relationship of treatment adherence to the risk of death after myocardial infarction in women. JAMA 1993;270:742-4.
29. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002;288:49-57.
30. Anonymous. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.